Emergent BioSolutions (NYSE:EBS) Upgraded at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

A number of other brokerages have also recently issued reports on EBS. Benchmark raised their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research report on Friday.

Emergent BioSolutions Trading Down 0.4 %

Emergent BioSolutions stock traded down $0.04 during trading hours on Tuesday, reaching $9.37. 1,111,748 shares of the company’s stock traded hands, compared to its average volume of 1,008,043. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The firm’s 50 day moving average is $9.36 and its 200-day moving average is $9.17. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm has a market capitalization of $507.70 million, a price-to-earnings ratio of -2.29 and a beta of 1.60.

Hedge Funds Weigh In On Emergent BioSolutions

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new position in Emergent BioSolutions during the second quarter worth about $93,000. Stifel Financial Corp acquired a new stake in shares of Emergent BioSolutions during the third quarter worth about $96,000. Morse Asset Management Inc bought a new position in shares of Emergent BioSolutions during the 2nd quarter valued at about $97,000. FORA Capital LLC acquired a new position in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $103,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Emergent BioSolutions during the 3rd quarter worth approximately $141,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.